At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 13 enrolled
Drug / intervention
AMDX2011Pdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prospective Randomized Open, Blinded Endpoint (PROBE) Study of AMDX-2011P as a Retinal Tracer in Subjects With Neurodegenerative Diseases Associated With Amyloidogenic Proteinopathy
In Brief
A Phase 2 clinical trial evaluating AMDX2011P for Parkinson Disease and Amyotrophic Lateral Sclerosis. Completed, enrolled 13 participants across 2 sites.
Detailed Summary
The purpose of this research study is to assess safety and tolerability of a single intravenous (given through a vein) dose of the investigational retinal tracer AMDX-2011P in patients with neurodegenerative diseases (Parkinson's disease and ALS).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson Disease, Amyotrophic Lateral Sclerosis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2023202420252026
Enrollment StartAug 2022
First PostedSep 2022
Primary CompletionMar 2023
TodayJul 2026
First PostedSep 15, 2022
Enrollment StartAug 24, 2022
Primary CompletionMar 15, 2023
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 3.8 years ago
Interventions
AMDX2011Pdrug
AMDX2011P single bolus injection intravenous for diagnostic review